OncoTargets and Therapy

Dovepress
open access to scientific and medical research

Open Access Full Text Article

CORRIGENDUM

Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A [Corrigendum]

Zheng Y, Gao Y, Li X, et al. *Onco Targets Ther*. 2018;11:4965–4977.

On page 4972, the authors found an error in which the images for Figure 4A PC3 Blank and Figure 4B 22RV1 Blank were mistakenly duplicated. Upon realising the error, the authors repeated the knockdown experiment described in Figure 4 and were able to show results consistent with those described in the original article. The authors provided a description of the experiment procedure used for the relative colony counts and the raw data from both the original and repeated experiments used to generate the results shown in Figure 4A and Figure 4B. See revised Figure 4 below.

The authors and the editor have confirmed that the correction of the images has no significant impact on the conclusions of the study.

The authors wish to apologise for this error.



OncoTargets and Therapy downloaded from https://www.dovepress.com/
For personal use only.

© 2019 Zheng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

OncoTargets and Therapy Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal